Page 417 - Environmental Nanotechnology Applications and Impacts of Nanomaterials
P. 417

400   Potential Impacts of Nanomaterials

























        Figure 11.2  Transmission electron micrograph of a human epidermal keratinocyte
        that was exposed to 0.4 mg/ml of the fullerene-based amino acid for 24 hours. Arrows
        depict agglomerates in vacuoles around the periphery of the nucleus.





        periphery of the nucleus in large vacuoles (Figure 11.2). Human epi-
        dermal keratinocytes exposed to fullerene-based amino acid solu-
        tions ranging from 0.04–0.004 mg/ml resulted in a significant
        decrease in viability and a statistically significant increase in IL-8
        at a dose of 0.04 mg/ml over periods of 8, 12, and 24 hours. IL-6 and
        IL-1β were greater at 24 and 48 hours, but there was no significant
        TNF-α or IL-10 expression. (Rouse et al., 2006).
          Studies were also conducted with a fullerene-substituted phenylala-
        nine derivative of a nuclear localization peptide sequence to evaluate the
        effects on mechanical stressors such as repetitive flexing motion. Skin
        flexed for 60 or 90 minutes  and dosed with the fullerene or left unflexed
        (control) was studied by confocal laser microscopy which depicted pen-
        etration after 60 and 90 minutes of flexion and 8 hours of flow-through
        diffusion and further penetration after 24 hours of flow-through diffu-
        sion. This study showed that mechanical flexion caused an increase in
        nanoparticle penetration through skin (Rouse et al., 2007).
          In contrast with these studies suggesting toxicity of various fullerenes
        and their derivatives, other studies have concluded that fullerenes
        may have beneficial effects for cells. Numerous studies have also been
        published that show functionalized fullerenes to be therapeutically
        useful in the treatment of a number of diseases. A balanced benefit-
        risk assessment must be made before these substances are released for
        human use.
   412   413   414   415   416   417   418   419   420   421   422